Translational Sciences Inc.
Paradise Valley, AZ
- UEI
- EFQDNXDDTBM4
- CAGE
- 4TVM7
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 6725 E Rovey Ave, Paradise Valley, AZ 85253, USA
- Website
- translationalsciences.com
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| Cincinnati Univ Of | UH3NS125023 | $287,664 | |
| Cincinnati Univ Of | UG3NS125023 | $1,632,664 |
Similar vendors
About the company
Translational Sciences Inc., also doing business as Translational Sciences Inc., is a for-profit organization that specializes in providing innovative solutions in the field of translational sciences, including advanced analytics for drug discovery and development. The company has been registered to receive federal awards since 2007 and is structured as a Subchapter S Corporation.
Through several prime federal grant awards from the National Institutes of Health, primarily the National Heart, Lung, and Blood Institute, Translational Sciences Inc. has conducted research and development activities focused on novel therapeutic approaches for treating venous thromboembolism, pulmonary embolism, and acute ischemic stroke. Significant funding has been provided to develop a monoclonal antibody therapy targeting α2-antiplasmin for dissolving intravascular thrombi, as well as an ultra-specific monoclonal antibody inhibitor of matrix metalloproteinase-9 to reduce neurovascular matrix degradation and hemorrhage in ischemic stroke patients receiving thrombolytic or thrombectomy treatment. Additionally, Translational Sciences Inc. has received a sub-award from the University of Cincinnati for the Strategy for Improving Stroke Treatment Response (SISTER) Trial. The company's work through these federal grants aims to advance novel therapeutics that improve outcomes and reduce complications for patients suffering from thrombotic and ischemic conditions.
Quick answers
Is Translational Sciences Inc. registered in SAM.gov?
Yes. Translational Sciences Inc.'s SAM.gov registration is active through June 8, 2027.
What is Translational Sciences Inc.'s most recent federal award?
Translational Sciences Inc.'s most recent federal grant award is Novel ?2-antiplasmin inactivation for lysis of intravascular thrombi (nail-IT) trial - each year venous thromboembolism… (R44HL158376), from National Heart Lung and Blood Institute (NIH), on July 5, 2021.
On GovTribe
See Translational Sciences Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors